Bruno François

Bruno is specialist in Intensive Care medicine at the University Hospital of Limoges, France. He works in a 30 bed medical/surgical ICU and since 2008 is the head of the Limoges Clinical Investigation Center (Inserm CIC-P 1435) of which main expertise is Infectious Diseases in critically ill patients. He has been national and international coordinator for numerous emergency trials especially in Sepsis, VAP and VAP prevention, and has participated in several advisory boards for Sepsis and VAP multinational trials, independent Clinical Evaluation Committees and Adjudication Committees. He is more specifically interested in new drugs and innovative strategies in critically ill patients and more especially anti-infective monoclonal antibodies used both pre-emptively and adjunctively. He is author of many publications in Infectious Disease in the ICU especially about Sepsis and VAP and is also reviewer for several medical journals in the ICU field. He has an expertise in the practical bedside organization of clinical research in the ICU. He has also an interest in more translational studies and research about the immunological disorders of Sepsis evaluated by flow cytometry and its potential treatments. He created the CRICS network dedicated to clinical research in Sepsis trials in 2007 and has been the coordinator of the French F-CRIN certified CRICS-TRIGGERSEP research network which integrates all research activities in Sepsis from basic science to clinical trials. Since 2012, he is co-coordinating the COMBACTE-Net consortium within the IMI framework as academics partners and has been leading trials in collaboration with pharmaceutical companies developing new therapeutic pre-emptive approach of VAP with monoclonal antibodies against Staphylococcus aureus and Pseudomonas aeruginosa. Since 2021, he is a member of the coordinating committee of Ecraid, the first academic infrastructure in Europe that offers a single point of access to a pan-European clinical research network for infectious diseases. Since 2021, he is co-coordinating PROMISE which is a French meta-network dedicated to antimicrobial resistance within a one-health approach.